Markets PCRX

Pacira BioSciences Announces Repurchase Authorization

April 18, 2025 — 03:29 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Pacira BioSciences (PCRX) said its Board of Directors has authorized a share repurchase program of up to an aggregate of $300 million with respect to the common stock, replacing the prior authorization. The share repurchase authorization expires at the end of December 2026.

Frank Lee, CEO of Pacira BioSciences, said, "This increased share repurchase authorization underscores the Board's confidence in Pacira's growth strategy and our commitment to delivering value to shareholders. Our recently established EXPAREL exclusivity runway extends to 2039 and provides long-term visibility that empowers us to confidently execute our 5x30 strategy as we generate significant cash flow."

Also, Pacira said its Board and management team are committed to enhancing the company's operational efficiency and expects to prioritize opportunities to drive margin expansion at the pre-tax net income level to further enhance value for shareholders.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
PCRX

Latest Articles
Data is currently not available